Insights from 2023 ESMO World Congress on Gastrointestinal Cancer Annual Meeting
2023 ESMO WCGIC Insights: "First Report of Comprehensive Biomarker Analyses From CheckMate 577 Trial - Adjuvant Nivo vs. Placebo in Resected EC/GEJC Following Neoadjuvant CRT"
Comments 0
Login to view comments.
Click here to Login
